Evidence map›Paper›PMID 34155198›Full record

Trial reportBlood cancer journal2021

Detection of minimal residual disease by next generation sequencing in AL amyloidosis.

Shayna Sarosiek, Cindy Varga, Allison Jacob, Maria Teresa Fulciniti, Nikhil Munshi, Vaishali Sanchorawala

Open access · goldAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Shayna SarosiekSection of Hematology & Medical Oncology, Boston Medical Center, Boston, MA, USA.ORCID 0000-0002-0075-6735
Cindy VargaThe John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Allison JacobAdaptive Biotechnologies, Seattle, WA, USA.
Maria Teresa FulcinitiDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1432-9742
Nikhil MunshiDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7344-9795
Vaishali SanchorawalaSection of Hematology & Medical Oncology, Boston Medical Center, Boston, MA, USA. Vaishali.Sanchorawala@bmc.org.ORCID 0000-0002-6307-2445
Boston University · USDana-Farber Cancer Institute · USAdaptive Biotechnologies (United States) · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Flow CytometryHigh-Throughput Nucleotide SequencingImmunoglobulin Light-chain AmyloidosisBiomarkers, TumorDisease-Free SurvivalFemaleHumansMaleNeoplasm, ResidualSurvival RateBiomarkers, Tumor

Identifiers

PMID34155198
PMCPMC8217177
OpenAlexW3174903776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.